Axial spondyloarthritis: obesity is common and is associated with poor clinical outcome
A study has assessed the prevalence of overweight and obesity in a large cohort of patients with axial spondyloarthritis ( axSpA ) in comparison with the general population. To explore the relationship of body mass index ( BMI ) with clinical outcome in axial spondyloarthritis.
Patients from the Groningen Leeuwarden Axial SpA cohort who visited the outpatient clinic in 2011/2012 were included in this cross-sectional analysis.
Body weight, height, disease activity, physical function, and quality of life ( QoL ) were assessed. Patients were divided into normal weight ( BMI less than 25 kg/m2 ), overweight ( BMI greater than or equal to 25 to less than 30 kg/m2 ), and obese ( BMI greater than or equal to 30 kg/m2 ).
BMI data for the general population in the same demographic region, matched for age and sex, were obtained from the LifeLines Cohort Study.
Of the 461 patients with axial spondyloarthritis, 37% were overweight and 22% were obese.
In the LifeLines cohort ( n=136,577 ), 43% were overweight and 15% were obese.
Overweight and obese patients were older, had longer symptom duration, and had more comorbidities, especially hypertension.
Further, obese patients had significantly higher disease activity, worse physical function, and worse quality of life than overweight and normal weight patients ( mean Bath Ankylosing Spondylitis Disease Activity Index 4.5, 3.5, 3.8; mean Ankylosing Spondylitis Disease Activity Score 2.8, 2.2, 2.3; median C-reactive protein 5, 3, 3 mg/l; median erythrocyte sedimentation rate 13, 8, 8 mm/h; median Bath Ankylosing Spondylitis Functional Index 5.2, 2.9, 2.9; median Ankylosing Spondylitis QoL Questionnaire 8, 4, 5, respectively ).
After adjustment for potential confounders, obesity proved to be an independent predictor of worse clinical outcome.
In this large observational cohort study, obesity is more common in axial spondyloarthritis than in the general population and it is associated with worse clinical outcome. ( Xagena )
Maas F et al, J Rheumatol 2015; Epub ahead of print
The European Commission ( EC ) has granted marketing authorization for Hulio, a biosimilar to Humira ( Adalimumab ), for...
Ixekizumab in ankylosing spondylitis: positive results from two phase 3 studies, COAST-V and COAST-W
Findings from two phase 3 studies, COAST-V and COAST-W, in adults with ankylosing spondylitis ( AS ), also referred to...
The European Commission has approved Humira ( Adalimumab ) for the treatment of active moderate to severe hidradenitis suppurativa...
Enbrel for the treatment of non-radiographic axial spondyloarthritis, approved by European Commission
The European Commission ( EC ) has granted a licence extension for Enbrel ( Etanercept ) in the treatment of...
The European Medicines Agency’s ( EMA’s ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...
The Food and Drug Administration ( FDA ) has approved Cimzia ( Certolizumab pegol ) for the treatment of adults...
Cimzia in patients with severe active axial spondyloarthritis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to...